Clinicians should remind patients that clotting factors don’t generally need to be stored in the fridge because, a study from Italy suggests, this may influence their satisfaction with treatment (Pat Pref Adherence 2018;12:431-41).
The survey of 200 people with moderate or severe haemophilia A in seven countries (including the UK) determined how product features affected patients’ perceptions of recombinant Factor VIII formulations. Respondents were asked to state a preference for one of three products with different attributes (origin of factor, storage temperature, storage shelf life, reconstitution device, stability after mixing and administration frequency).
The average duration of use of factor replacement was 8 years. Seventeen percent of respondents expressed general dissatisfaction with their current products. The 88% of respondents who believed they should store factors in the fridge were less likely to be satisfied with their product, more concerned about storage temperature, to report greater restriction of daily activities and to spend more time preparing and injecting compared with those patients who opted for storage at room temperature. Choice of factor product was driven by the origin of Factor VIII (plasma-derived or recombinant), storage temperature, reconstitution device and administration frequency.